Metsera (NASDAQ:MTSR) Shares Gap Up - Should You Buy?

Key Points

• Metsera Inc. (NASDAQ:MTSR) shares opened at $33.57, a gap up from the previous close of $32.39, but last traded at $30.25 with a trading volume of 402,169 shares.
• Analysts have bullish expectations for Metsera, with Guggenheim raising their price target from $56.00 to $62.00 and Wells Fargo setting a $65.00 target, while the consensus rating remains a "Buy" with an average target of $55.00.
• Despite recent analyst optimism, Metsera shares have declined by 9.2% and the company reported earnings of ($0.66) per share for the last quarter.

Metsera Inc. (NASDAQ:MTSR - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $32.39, but opened at $33.57. Metsera shares last traded at $30.25, with a volume of 402,169 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Guggenheim increased their price target on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Wells Fargo & Company began coverage on Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $55.00.

Metsera Trading Up 0.8%

The firm has a 50-day simple moving average of $33.31 and a 200-day simple moving average of $28.33.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Institutional Trading of Metsera

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC bought a new stake in Metsera during the 2nd quarter valued at $373,000. Rafferty Asset Management LLC acquired a new stake in shares of Metsera in the 2nd quarter worth $549,000. Eventide Asset Management LLC boosted its position in shares of Metsera by 58.5% in the 2nd quarter. Eventide Asset Management LLC now owns 396,160 shares of the company's stock worth $11,271,000 after purchasing an additional 146,160 shares in the last quarter. EcoR1 Capital LLC boosted its position in shares of Metsera by 443.1% in the 2nd quarter. EcoR1 Capital LLC now owns 271,529 shares of the company's stock worth $7,725,000 after purchasing an additional 221,529 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Metsera by 100.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company's stock worth $46,000 after purchasing an additional 800 shares in the last quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.